[go: up one dir, main page]

MX2015011651A - Formas cristalinas de d-glucitol,1-desoxi-1-(metilamino)-,1-(6-ami no-3,5-difluoropiridin-2-il)-8-cloro-6-fluoro-1,4-dihidro-7-(3-hi droxiazetidin-1-il)-4-oxo-3-quinolincarboxilato. - Google Patents

Formas cristalinas de d-glucitol,1-desoxi-1-(metilamino)-,1-(6-ami no-3,5-difluoropiridin-2-il)-8-cloro-6-fluoro-1,4-dihidro-7-(3-hi droxiazetidin-1-il)-4-oxo-3-quinolincarboxilato.

Info

Publication number
MX2015011651A
MX2015011651A MX2015011651A MX2015011651A MX2015011651A MX 2015011651 A MX2015011651 A MX 2015011651A MX 2015011651 A MX2015011651 A MX 2015011651A MX 2015011651 A MX2015011651 A MX 2015011651A MX 2015011651 A MX2015011651 A MX 2015011651A
Authority
MX
Mexico
Prior art keywords
hydroxyazetidin
deoxy
methylamino
oxo
fluoro
Prior art date
Application number
MX2015011651A
Other languages
English (en)
Inventor
Hanselmann Roger
M Reeve Maxwell
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of MX2015011651A publication Critical patent/MX2015011651A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere, en general a formas Cristalinas de D-glucitol, 1-desoxi-1-(metilamino)-,1-(6-amino-3,5-difluoropir idin-2-il)-8-cloro-6-fluoro-1,4-dihidro-7-(3-hidroxiazetidin-1-il )-4-oxo-3-quinolincarboxilato anhidro, composiciones que comprenden el mismo, y métodos para elaborarlo. La Delafloxacina es un antibiótico de fluoroquinolona con la estructura química y el nombre químico 1-desoxi-1-(metilamino)-,1-(6-amino-3,5-difluoro piridin-2-il)-8-cloro-6-fluoro-1,4-dihidro-7-(3-hidroxiazetidin-1 -il)-4-oxo-3-quinolincarboxilato. Los estudios han indicado la existencia de tres polimorfos anhidros de delafloxacina, así como también un trihidrato y solvatos de metanol y etanol.
MX2015011651A 2013-03-08 2014-03-07 Formas cristalinas de d-glucitol,1-desoxi-1-(metilamino)-,1-(6-ami no-3,5-difluoropiridin-2-il)-8-cloro-6-fluoro-1,4-dihidro-7-(3-hi droxiazetidin-1-il)-4-oxo-3-quinolincarboxilato. MX2015011651A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361775089P 2013-03-08 2013-03-08
PCT/US2014/021946 WO2014138639A1 (en) 2013-03-08 2014-03-07 Crystalline forms of d-glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3, 5-difluoropyridine-2-yl)-8-chloro-6-fluoro-1, 4-dihydro-7-(3-hydroxyazetidin-1-yl)-4-oxo-3-quinolinecarboxylate

Publications (1)

Publication Number Publication Date
MX2015011651A true MX2015011651A (es) 2016-08-08

Family

ID=51492015

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011651A MX2015011651A (es) 2013-03-08 2014-03-07 Formas cristalinas de d-glucitol,1-desoxi-1-(metilamino)-,1-(6-ami no-3,5-difluoropiridin-2-il)-8-cloro-6-fluoro-1,4-dihidro-7-(3-hi droxiazetidin-1-il)-4-oxo-3-quinolincarboxilato.

Country Status (14)

Country Link
US (1) US20160046603A1 (es)
EP (1) EP2964652A4 (es)
JP (1) JP2016511273A (es)
CN (1) CN105189513A (es)
AR (1) AR095203A1 (es)
AU (1) AU2014225392A1 (es)
BR (1) BR112015021725A2 (es)
CA (1) CA2903755A1 (es)
EA (1) EA201591668A1 (es)
HK (1) HK1219476A1 (es)
IL (1) IL241045A0 (es)
MX (1) MX2015011651A (es)
TW (1) TW201514165A (es)
WO (1) WO2014138639A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105693695A (zh) * 2014-11-24 2016-06-22 重庆医药工业研究院有限责任公司 一种德拉沙星葡甲胺盐的晶型及其制备方法
CN105017223B (zh) * 2015-07-08 2017-08-01 扬子江药业集团有限公司 德拉沙星葡甲胺晶型i及其制备方法
CN105017224A (zh) * 2015-07-10 2015-11-04 扬子江药业集团有限公司 一种德拉沙星葡甲胺晶型的制备方法
CN106916142A (zh) * 2015-12-25 2017-07-04 江苏奥赛康药业股份有限公司 一种制备高纯度德拉沙星的方法
CN110467600A (zh) * 2018-05-10 2019-11-19 上海度德医药科技有限公司 一种德拉沙星葡甲胺盐晶型l及其制备方法
CN113018268B (zh) * 2019-12-25 2024-02-02 鲁南制药集团股份有限公司 一种注射用德拉沙星葡甲胺冻干制剂及其制备方法
WO2022240897A1 (en) * 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung
CN116514775B (zh) * 2022-01-20 2024-11-29 安徽普利药业有限公司 一种徳拉沙星葡甲胺盐新晶型及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57134482A (en) * 1981-02-13 1982-08-19 Dainippon Pharmaceut Co Ltd 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8- naphthyridine-3-carboxylic acid-3/2 hydrate and its preparation
EP3056492B1 (en) * 2004-10-08 2021-09-22 AbbVie Inc. Meglumine salt and crystalline forms thereof of a drug (delafloxacin)
US20070238719A1 (en) * 2005-05-10 2007-10-11 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
TW200744598A (en) * 2005-09-28 2007-12-16 Daiichi Seiyaku Co Process for the production of freeze-dried preparations containing quinolones
WO2008085913A1 (en) * 2007-01-04 2008-07-17 Rib-X Pharmaceuticals, Inc. Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections
WO2010056872A2 (en) * 2008-11-15 2010-05-20 Rib-X Pharmaceuticals, Inc. Antimicrobial compositions

Also Published As

Publication number Publication date
CN105189513A (zh) 2015-12-23
EP2964652A4 (en) 2016-10-12
TW201514165A (zh) 2015-04-16
EA201591668A1 (ru) 2016-02-29
AU2014225392A1 (en) 2015-09-24
BR112015021725A2 (pt) 2017-07-18
AR095203A1 (es) 2015-09-30
JP2016511273A (ja) 2016-04-14
US20160046603A1 (en) 2016-02-18
HK1219476A1 (zh) 2017-04-07
EP2964652A1 (en) 2016-01-13
WO2014138639A1 (en) 2014-09-12
IL241045A0 (en) 2015-11-30
CA2903755A1 (en) 2014-09-12

Similar Documents

Publication Publication Date Title
MX2015011651A (es) Formas cristalinas de d-glucitol,1-desoxi-1-(metilamino)-,1-(6-ami no-3,5-difluoropiridin-2-il)-8-cloro-6-fluoro-1,4-dihidro-7-(3-hi droxiazetidin-1-il)-4-oxo-3-quinolincarboxilato.
EP2566477A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
PH12016500676A1 (en) Pyrimidine fgfr4 inhibitors
PH12014502169A1 (en) N-cyclylamides as nematicides
MX2016005054A (es) Compuestos heteroarilo como inhibidores de tirosina cinasa de bruton (bkt) y usos de los mismos.
JO2887B1 (en) Spiro-pyridine compounds as ORL-1 receptor antagonists
CR20120113A (es) (heteroarilmetil)tiohidantoinas sustituidas como drogas anticancer
PH12016500250A1 (en) Novel triazolo [4,5-d] pyrimidine derivatives
MX2016007176A (es) Composiciones y metodos para obtener (r)-reticulina y precursores de las misma.
PH12015501933B1 (en) Novel pyridine derivatives
MX2015009719A (es) Inhibidores benzoquinolona de vmat2.
PH12015500376B1 (en) Novel bicyclic pyridinones
CU20160004A7 (es) Bencil-1 h-pirazolo[3,4-b]piridinas
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
PH12015501807B1 (en) Vortioxetine manufacturing process
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
IN2013MU03862A (es)
ZA201604932B (en) N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase
MX345142B (es) Derivados de aminoalquilpirimidina como antagonistas del receptor h4 de histamina.
MX342960B (es) Derivados de cromeno.
IN2015DN00085A (es)
MX363458B (es) Nuevos derivados de tetrazolona.
WO2014172363A3 (en) Combretastatin analogs
PL3004058T3 (pl) Związki-inhibitory acetylcholinesterazy i agoniści receptorów serotoninergicznych 5ht4, o działaniu propamięciowym, ich sposoby wytwarzania i zawierające je kompozycje farmaceutyczne
IN2013MU02635A (es)